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The overarching goals of treatments for orthopedic conditions are generally to improve or restore function and
alleviate pain. Results of clinical trials are generally used to determine whether a treatment is efficacious; however, a
statistically significant improvement may not actually be clinically important, i.e., meaningful to the patient. To
determine whether an intervention has produced clinically important benefits requires a two-step process: first,
determining the magnitude of change considered clinically important for a particular measure in the relevant
population and, second, applying this yardstick to a patient’s data to determine whether s/he has benefited from
treatment. Several metrics have been devised to quantify clinically important differences, including the minimum clinically
important difference (MCID) and clinically important difference (CID). Herein, we review the methods to generate the
MCID and other metrics and their use and interpretation in clinical trials and practice. We particularly highlight the many
pitfalls associated with the generation and utilization of these metrics that can impair their correct use. These pitfalls
include the fact that different pain measures yield different MCIDs, that efficacy in clinical trials is impacted by various
factors (population characteristics, trial design), that the MCID value is impacted by the method used to calculate it
(anchor, distribution), by the type of anchor chosen and by the definition (threshold) of improvement. The MCID is also
dependent on the population characteristics such as disease type and severity, sex, age, etc. For appropriate use, the
MCID should be applied to changes in individual subjects, not to group changes. The MCID and CID are useful tools to
define general guidelines to determine whether a treatment produces clinically meaningful effects. However, the many
pitfalls associated with these metrics require a detailed understanding of the methods to calculate them and their
context of use. Orthopedic surgeons that will use these metrics need to carefully understand them and be aware of
their pitfalls.
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Musculoskeletal conditions are often associated with re-
duced function and pain. In most common orthopedic
conditions, patients and clinicians determine the success
of treatment based on two main outcomes: pain reduction
and functional improvement [1]. Whether a treatment is
efficacious is determined by reviewing the results of ran-
domized controlled trials (RCTs). The primary thrust of
RCTs is to demonstrate a statistically significant difference* Correspondence: nkatz@analgesicsolutions.com
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unless otherwise stated.in outcome between treatment groups. Statistical sig-
nificance, however, does not necessarily imply clinical
significance, or clinical importance, i.e., whether the
observed improvement is meaningful to the patient
[2-5]. Very small treatment effects, too small to be
meaningful to patients, will be statistically significant if
the sample sizes are large enough. Treatments that
produce large and clinically important benefits may fail
to achieve statistical significance if the sample size was too
small. To this end, clinical researchers have introduced a
series of metrics to determine whether improvements
after treatment are clinically important [5].
Determining whether a treatment effect is clinically
significant is paramount for a variety of stakeholders inis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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velop treatment guidelines and formularies, make regula-
tory decisions, set market access and reimbursement
policies, conduct systematic reviews, and practicing ortho-
pedists who need to make informed decisions regarding
patient treatments. Errors in determination of clinical
significance of interventions for orthopedic conditions
may have high consequences. These stakeholders bear
a responsibility to understand how clinical importance is
determined and ensure that decisions based on estimates
of clinical importance are based on appropriate methods.
Other aspects of treatment should be considered in
the choice of one orthopedic intervention over another.
These include impact on physical function, quality of life
(both psychological and social aspects), tolerability, con-
venience, availability, physician’s preference and experience,
cost, and alternative treatment options [6]. This review fo-
cuses on the determination of the clinical importance of
changes in pain intensity (PI), usually the primary outcome
measure in clinical trials of these conditions.
Ultimately, this review should help those who generate
the metrics of clinically important changes, and those who
use these metrics to make informed decisions regarding
orthopedic treatments. To this end, we will review how
these metrics are generated, and how these metrics can
and should be interpreted to make informed decisions,
highlighting the many pitfalls of these two processes.
Overview of the process
Two processes
In determining whether an intervention studied in an
RCT has produced a clinically important benefit, two
different processes are involved (Figure 1). The first is toFigure 1 Flow chart illustrating the overall process of determining CI
factors include: disease, impact on quality of life, tolerability, convenience, adetermine what magnitude of change in PI is considered
clinically important in the relevant treatment population.
To accomplish this goal, one needs to collect data from
clinical trial evaluating treatments for pain in the specific
condition (1a) and these data need to be analyzed to
determine which changes in pain are considered clinically
important. For example, one can determine through this
process that a decrease in pain of 20 mm on the 0–
100 mm visual analog scale (VAS) in a patient with knee
osteoarthritis (OA) is a clinically important change.
The second process consists of using the metrics de-
termined in the first process as a yardstick to determine
whether a treatment has produced a clinically important
change in a particular patient. For instance, an OA patient
who has a decrease in pain of 30 mm on VAS after treat-
ment is considered to have a clinically important response
(as determined in the first process), i.e., the patient is con-
sidered as a responder to the treatment. Whether the
treatment produces a clinically meaningful impact is then
determined by comparing the proportion of “responders”
on active treatment compared to control.
Metrics of clinically important changes
The most widely used metrics of clinical important
changes are described and defined in Table 1. They are
typically generated by determining longitudinal improve-
ment, i.e., comparing treatment outcome from pre- to
post-treatment.
How do these metrics fit together? If the MDC on a
pain scale was determined to be 20 units, the minimum
clinically important difference (MCID) threshold 30 units,
and the clinically important difference (CID) 45 units, this
means that the pain scale cannot detect changes below 20D and using it to determine treatment efficacy. (Asterisk) Other
vailability, cost, and alternative treatments.
Table 1 Metrics of clinically important changes
Metric Definition Notes
Smallest detectable difference (SDD) The amount of difference in an outcome measure for
which anything smaller cannot be reliably distinguished
from random error in the measurementMinimal detectable change (MDC)
Minimal clinically important difference (MCID) The smallest change or difference in an outcome
measure between pre- and post-treatment perceived
as beneficial (or detrimental) by the patient [7-9]
Can be used to measure improvement
and worsening
Minimal clinically important change (MCIC)
Minimal clinically important improvement (MCII) Only measures improvements
Clinically important difference (CID) The difference in outcome measure that is considered
clinically important/meaningful
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ically important by patients is 30 units, and the change in
pain score considered clinically important is 45 units
(Figure 2).
Calculating the SDD, MCD, MCID, and CID
Data generation
To determine MCID in painful disorders, one needs to
first collect clinical trial data with a pain endpoint. The
clinical data used to make determinations of the smal-
lest detectable difference (SDD)/MCID/CID should be
as similar as possible (same population, same pain end-
point, similar treatment if applicable, similar study de-
sign) as the trial in which the MCID is used as a
yardstick. This is because many factors can influence
the effect size—and therefore the MCID—in a clinical
trial.
First, as expected, the MCID is specific to the pain meas-
ure and scale used: an MCID calculated using 0–100 mm
VAS pain is not equal or convertible to an MCID using
the 0–10 numerical rating scale (NRS). Therefore, to de-
termine whether the decrease in PI in a trial has reached
the MCID, one needs to compare the trial results withFigure 2 Metrics of clinical importance—theoretical example
for a pain measure. MDC (blue dotted line), MCID (green dotted
line), and CID (purple dotted line) are illustrated. The improvement
of pain score over time (weeks) is shown for three theoretical
patients (Pt1, Pt2, and Pt3). After week 4, the treatment is considered
successful for Pt1 (change in pain > CID), the treatment is marginally
successful for Pt2 (change in pain > MCID but < CID), and treatment
failed in Pt3 (change in pain < MDC).MCID values calculated with the same pain scale. Tables 2
and 3 provide the MCID values calculated for different
pain scales in different publications.
Interestingly, the MCID does not depend on the type
of treatment [11,12,23]. For instance, the MCID on VAS
for pain was ~25 mm in OA patients regardless of treat-
ment (NSAIDs, THR, TKR, or rehabilitation) [11], i.e., im-
provement is improvement regardless what produced it.
MCID may not be the same across diseases unless this
has been demonstrated. Stauffer et al. [23] found that
the MCID in VAS pain is different between patients with
knee OA, hip OA, and back pain, while Farrar et al. [11]
found similar MCID for pain NRS in patients in OA,
painful diabetic, neuropathy, postherpetic neuralgia, low
back pain, and fibromyalgia.
The MCID also varies with the severity of the disease:
the MCID is larger at higher baseline pain levels, sug-
gesting that patients with severe pain require a larger
amount of pain relief to report being satisfied (Table 4)
[23]. This is corroborated by data from Quintana [15]
and Farrar [11] (Table 2).
Calculating SDD and MDC
There are two methods of estimating SDD/MDC which
are purely statistical [23]: SDD is calculated using the
limits of agreement method (a.k.a., the Bland and Altman
method [24]) and MDC using the standard error of the
mean (SEM). One problem with the SDD is that its
value depends on the sensitivity of the statistical method
used [25].
Calculating MCID or CID
There are four methods to calculate the MCID: consensus,
anchor-based, distribution-based, or a combination of
anchor- and distribution-based methods.
Consensus methods
In the consensus method, a panel of expert is convened
and each expert provides his/her best estimate of the
MCID until a consensus is achieved. For instance, the
consensus method was used to define a decrease in PI
from a baseline of ≥20% (moderate improvement) as a
Table 2 Example of calculations of MCID and CID in pain score in OA patients
Reference (treatment) Method Categories in anchor Definition of MCID or CID improvement MCID or CID
Pain on VAS (0–100 mm scale)
Tubach 2005 (NSAIDs) [10] Anchor—PGA None, poor, fair, good, excellent 75th percentile of the chang score among
patients whose evaluation of sponse to
treatment (on PGA) was “goo (MCID)
−19.9 mm (knee)− 15.3 mm (hip)
Pain on NRS (0–10 pt)
Farrar 2001 [11] Anchor―PGIC Very much improved, much improved,
minimally improved, no change,
minimally worse, much worse,
very much worse
Decrease in pain score for pa nts “much
improved” (CID)
2 pt
Decrease in pain score for pa nts “very much
improved” (CID)
≥4 pt
ROC—PGIC Very much improved, much improved,
minimally improved, no change,
minimally worse, much worse,
very much worse
Decrease in pain score for pa nts “much
improved” (CID)
≥1.7 pt
Pain on WOMAC (on 0–100 pt scale, unless otherwise noted)
Ehrich 2000 (NSAIDs) [12] Anchor—PGA None, poor, fair, good, excellent Difference btw “none” and “p r” response
on PGA (MCID)
9.7 mm
Angst 2001 (inpatient rehabilitation) [13] Anchor—transition question Much worse, slightly worse, equal,
slightly better, much better
Difference btw “equal” and “ htly better”
groups (MCID)
0.75 pta
Escobar 2007 (TKR) [14] Anchor—transition question A great deal better, somewhat better,
equal, somewhat worse, a great deal
worse
Difference btw baseline scor d scores for
patients declaring changes “s ewhat better”
(MCID)
23 pt
Quintana 2012 (THR) [15]a Anchor—transition question Seven items from “a great deal better”
to “a great deal worse”
Mean change score for patien hose response
was “a little better” (MCID)
15, 23, 36 ptb
Anchor—PASS question Totally satisfied, slightly satisfied, not
satisfied, not at all satisfied
Mean change in score for th 5th percentile of
patients in the probability cur reporting being
totally satisfied or slightly satis (MCID)
20, 25, 25 ptb
ROC—PASS question Totally satisfied, slightly satisfied, not
satisfied, not at all satisfied
Patients reporting being totally tisfied or slightly
satisfied—optimal point on cu (MCID)
19, 25, 25 ptb
Escobar 2013 (TKR) [16] Anchor—transition question A great deal better, somewhat better,
equal, somewhat worse, a great deal
worse
Mean change in patients “so what better”
(MCID)
30 pt
ROC—transition question A great deal better, somewhat better,
equal, somewhat worse, a great deal
worse





Very satisfied, somewhat satisfied,
somewhat dissatisfied and very
dissatisfied

































Table 2 Example of calculations of MCID and CID in pain score in OA patients (Continued)
SF-36 bodily pain (0–100 pt scale)
Angst 2001 (inpatient rehabilitation) [13] Anchor—“transition”
questionnaire
Much worse, slightly worse, equal,
slightly better, much better
Improvement MCID = Difference btw “equal”
and “slightly better” (MCID)
7.8 pt for improvement
Escobar 2007 (TKR) [14] Anchor—“transition” question at
6 months or 2 years
A great deal better, somewhat better,
equal, somewhat worse, a great deal
worse
Difference btw baseline score and scores for
patients declaring changes “somewhat better”
(MCID)
17 pt
Btw between, PASS Patient Acceptable Symptom, THR total hip replacement, pt point, TKR total knee replacement.
aOn a 0–10 point scale.
bMCID is reported for different patients’ baseline pain, divided in tertiles.














Table 3 Examples of calculation of MCID or CID in pain scores in patients with painful spine conditions
Reference (treatment) Method Categories in anchor Definition of MCID or CID for improvement MCID or CIDa
Distribution-based approaches
Carreon 2013 (lumbar fusion surgery) [17] MDC N/A—no anchor used MDC defines the MCID 1.16 pt—back pain,
1.36 pt—leg pain
Gum 2013 (lumbar fusion surgery) [18] MDC N/A—no anchor used MDC defines the MCID 0.20 pt—back pain,
0.23 pt—leg pain
Anchor-based approaches
Gum 2013 (lumbar fusion surgery) [18] ROC—health transition
item on SF-36
Much worse, somewhat worse, about the same,
somewhat better, and much better








Carreon 2010 (cervical spine fusion) [19] ROC—Health transition
item of SF-36
Much better, somewhat better, about the same,
somewhat worse, much worse
Distinguish the “somewhat better” from
the “about the same” patients (MCID)
2.5 pt—arm and
neck pain
Copay 2008 (lumbar spine surgery) [20] Anchor—satisfaction
with results scale
Answers: definitively true, mostly true, don’t know,
mostly false, or definitively false to the following
five items: 1. “I can do the things I thought I would
be able to do after surgery”; 2. “I was helped as
much as I thought I would be by my surgery”; 3.
“My pain was reduced as much as I expected it to
be after surgery”; 4. “The benefits of my care outweighed
the setbacks it caused me”; 5. “All things considered, I
would have the surgery again for the same condition”




Solberg 2013 (lumbar discectomy) [21] Anchor—global perceived
scale of change
Completely recovered, much improved, slightly
improved, no change, slightly worse, much worse,
and worse than ever
Patient reporting to be “completely
recovered” or “much better” (CID)
2.5 pt—back pain,
3.5 pt—leg pain
Parker 2013 (anterior cervical discectomy
and fusion) [22]
ROC—NASS 1) The treatment met my expectations; 2) I did not
improve as much as I had hoped, but I would undergo
the same treatment for the same outcome; 3) I did not
improve as much as I had hoped, and I would not
undergo the same treatment for the same outcome;
and 4) I am the same or worse than before treatment
Patients with choice 1 classified as
responders; choices 2–4 are
non-responders (CID)
4.0 pt—VAS neck pain,
4.0 pt—VAS arm pain
Combination: NASS
anchor + MDCb
2.6 pt—VAS neck pain,
4.1 pt—VAS arm pain
NASS North American Spine Society patient satisfaction scale, N/A not applicable.
aAll MCID and CID data presented in this table are for the 0–10 NRS, except for Parker 2013 which uses a 0–10 mm VAS.














Table 4 MCID by patient population and tertile of
baseline VAS score
Patient population Baseline pain on VAS 0–100 mm
30–49 mm 50–65 mm >65 mm
Knee OA 11 27 37
Hip OA 7 24 30
Low back pain 9 19 29
Data are MCID for improvement in pain (VAS 0–100 mm).
Data are from Tubach et al. [10].
Figure 3 Calculating CID by the ROC method. This analysis defines
the sensitivity and specificity of different cutoffs of a predictor (e.g.,
pain) for an anchor (e.g., global change). The diagonal line represents a
test with no predictive value. The curve is the ROC analysis. The CID is
the cutoff of the predictor with the highest sensitivity and specificity
for predicting the anchor, i.e., the upper left most point on the ROC
curve (marked by an x on the graph). For example, the x might
represent 30% pain reduction as the best cutoff to predict “much
improved” on a PGIC.
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≥50% reduction in pain from the baseline corresponds
to “very much improved” on the Patient Global Impres-
sion of Change (PGIC), providing a cross-validation of
the consensus method [11]. The main problem with the
consensus method is that it is not based on the opinion
of the patient.
Anchor-based methods
In the anchor-based method, the pain scores are com-
pared with an external, independent, face valid criterion
(termed “anchor”) to determine a MCID in pain. The
anchor is generally a questionnaire in which patients re-
port their level of improvement, chosen based on its
good reliability and validity. Examples of anchors include
the PGIC, a “transition” question, the Patient Global
Assessment (PGA) of treatment effectiveness (Tables 2
and 3). Using these anchors, MCID can be calculated for
both improvement and worsening (most studies report
the MCID for improvement in pain).
The anchor can be used to create a receiver operated
characteristics (ROC) curve, a common approach for
determining the performance of diagnostic tests. The
ROC cutoff is the value for which the sum of % of false
positives and false negatives is the smallest (as illustrated
in Figure 3). Alternatively, the cutoff is the value for PI
reduction that best predicts a specified change in the
anchor (e.g., patients “much improved” on a PGIC).
Tables 2 and 3 show examples of anchor-based calcula-
tions of MCID or CID in pain in OA (Table 2) and in
painful spine conditions (Table 3).
Calculation of the MCID versus CID is based on the
anchor threshold. Calculating the MCID is based on
selecting patients with minimum improvement on the
anchor, while calculating the CID is based on selecting
patients with great improvement. For instance, Gum
[18] defined the MCID for 0–10 NRS as the mean
change in PI in patients reporting feeling “somewhat
better” and the CID as the change in PI in patients
“much better” (Table 3); with these cutoffs, patients with
a decrease in back PI of ≥3.1 points on the 0–10 NRS
can be considered as minimally improved (MCID), while
those with a decrease in PI of ≥5.3 points can be consid-
ered greatly improved (CID) (Table 3).There are several problems associated with anchor-
based approaches. First, they are not suitable for con-
ditions where most patients will improve and only a
few remain unchanged. Second, they do not take into
account the variability of the sample. The optimal cutoff is
an average; some patients require smaller or larger
changes in PI, for example, to feel “much improved.”
Third, there are inherent problems associated with an-
chors for pain: (i) there is no objective measure of im-
provement in pain since pain is a subjective experience;
(ii) the anchors used often measure “improvement,”
which is a composite endpoint of pain and other factors,
such as function; and (iii) patients may have difficulty to
recall their initial status to accurately report their level of
improvement between pre- and post-treatment. Finally,
and most importantly, the degree of change in the anchor
that is meaningful to patients is usually uncertain, defeat-
ing the purpose of the anchor.
Distribution-based methods
Distribution-based methods use a statistical method to
measure the variability of a variable (e.g., PI) within
the sample and determine what degree of change in
that variable is generally of clinical importance. One
distribution-based approach uses the SEM: because
the SEM value reflects the imprecision of the measure-
ment, an MCID value below the SEM does not reflect a
true change. Another distribution-based method is the
Table 5 MCID values determined by different methods
Back pain
Method of MCID determination Anchor: HTIa Anchor: satisfactionb
Anchor-based
Average change 2.9 3.4
Change difference 1.4 1.9
ROC 2.5 2.5
Combination of anchor-based and distribution-based methods
SEM 0.4 0.4
MDC 1.2 1.2
From Copay 2008 [20].
aThe HTI questionnaire asks patients to compare their health after treatment
versus before treatment; the HTI answers are much better, somewhat better,
about the same, somewhat worse, and much worse. Patients reporting being
“somewhat better” or “about the same” were selected.
bThe satisfaction questionnaire has five items (statements): “I can do the
things I thought I would be able to do after surgery”; “I was helped as much
as I thought I would be by my surgery”; “My pain was reduced as much as I
expected it to be after surgery”; “The benefits of my care outweighed the
setbacks it caused me”; “All things considered, I would have the surgery again
for the same condition” to which patients can answer: definitively true, mostly
true, don’t know, mostly false, or definitively false. Patients classified as
“satisfied” and “don’t know” were selected.
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measurement error. In this approach, the MCID value
is defined as the upper value of the 95% confidence
interval (CI) for the average change score in non-
responders. The basis of using the SEM as MCID is
supported by the fact that MCIDs often turn out to be
around 1 SEM or ½ SD [27].
A few studies in painful orthopedic conditions have
used distribution-based methods to calculate the MCID
([17,18]; Table 3).
Distribution-based approaches have two important
limitations. First, they allow calculation of the MCID,
but not the CID. Second, they only define the minimum
value below which a change in pain score is hopefully
not due to measurement error.
Combination of anchor-based and distribution-based methods
One approach that combines both methods consists of
(i) defining responders/non-responders using an anchor
for improvement and then (ii) calculating the MCID
based on the MDC: the MCID is then equal to the upper
value of the 95% CI for the average change in pain score
seen in non-responders with the anchor. Using this com-
bined method, Parker et al. found a MCID of 2.6 points
for neck pain on VAS, compared to 4.1 points for the
ROC method [22]; the MCID for arm pain, however,
was similar with both methods (4.1 vs. 4.0 points, re-
spectively). Another way to do this is to use graphical
method that integrates both anchor- and distribution-
based approaches (see de Vet [28] for details). Using that
approach, de Vet [28] found an MCID of 4 points on
0–10 NRS pain with the combined approach, versus
2.5 points with the ROC approach alone. Although the
combined approach is more complex, it has the advan-
tage over the pure anchor-based method of accounting
for the variability of the sample.
Pitfalls with the calculation of the CID
The CID value is dependent on the methodology used
to calculate it. One study used a variety of anchor-based
(average change, change difference, and ROC) and com-
bination (anchor + SEM or MDC) methods and found
that the MCID could vary by seven- to eightfold for the
same anchor depending on the method used (Table 4)
[20]. Another study that used four anchor-based or com-
bination methods to calculate the MCID in pain in lum-
bar surgery found a wide range of MCID values, from
2.7 to 4.0 points for neck pain and from 2.4 to 4.2 points
for arm pain on a 0–10 VAS [22]. Finally, a study found
that the distribution-based MDC method yielded MCID
values ten times lower than an anchor-based method
(0.20 and 0.23 points by MDC vs. 3.1 and 2.8 points by
anchor for back and leg pain, respectively) (Table 3)
[18]. These studies clearly demonstrate that the MCIDvalue is dependent on the method used to calculate it.
However, this is not always the case, and some studies
have shown that two different methods can yield similar
MCID values ([11] [Table 2]; [15] [Table 2]; [22] [Table 3]
for arm pain only).
The MCID calculation using the anchor-based method
may also depend on the anchor type (PGIC, PGA, tran-
sition question, etc.). Various studies have compared the
MCID values with two anchors (Tables 2 and 4). While
in some instances, the anchor impacts the MCID ([15]
[Table 2]), it has little effects in other cases ([14] [Table 2];
[20] [Table 5]). Thus, the MCID cannot be assumed to be
robust to different methods of calculation.
Finally, the CID value depends on the threshold of
improvement. For instance, selecting patients “much
improved” versus “very much improved” on PGIC (anchor)
doubled the CID value from 2 to ≥4 points [11].
Using the MCID to determine treatment efficacy
Contextualizing the use of MCID as a yardstick
To appropriately use the MCID to determine the efficacy
of a treatment in a trial, one must use MCID values that
were calculated in a very similar context to the trial, i.e.,
for the same pain measure, in a similar patient population
(pain condition, severity of disease at baseline, baseline
characteristics), and using a similar trial design because
the MCID is dependent on all these factors, as discussed
above. In addition, one should be mindful of how the
MCID was calculated, as many factors influence the
MCID value, as discussed above (“Pitfalls in calculation
and interpretation of clinically important differences”
section). MCIDs values for a variety of pain measures,
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calculated and published. To find the appropriate MCID
yardstick to use among these publications, clinicians
should search through publication databases using search
words such as “MCID,” “pain,” accompanied with the
treatment of interest (e.g., lumbar surgery), and the meas-
urement of interest (e.g., VAS neck, back, or leg pain).
Then, it requires sorting through these publications to
find the most appropriate one (“Pitfalls in calculation and
interpretation of clinically important differences” section).
For instance, if one is interested in finding the MCID
value for VAS neck pain in a population of patients
undergoing anterior cervical discectomy and fusion, a
type of search as described above retrieved a very appro-
priate article from Parker et al. [22], which shows an
MCID value of 2.6 points.
Pitfalls in calculation and interpretation of clinically
important differences
 Pitfalls in generating efficacy data to calculate
metrics of clinically important differences
– Choice of pain measure: different pain measures
yield different MCIDs
– Efficacy in clinical trials is impacted by various
factors (population characteristics, trial design)
 Pitfalls in calculating the metrics of clinically
important differences
 The MCID value is impacted by:
– The method used to calculate it (anchor, ROC,
distribution)
– The type of anchor chosen
– The definition (threshold) of improvement
– The population characteristics such as disease
type and severity (baseline pain score)
 Pitfalls in applying the metrics of clinically
important differences to clinical trial data
– The appropriate MCID value has to be found or
calculated for the specific application
– In clinical trials, the MCID yardstick should be
applied to changes in individual subjects, not to
group changes; applying individual CIDs on a
group level is misleading
If the appropriate MCID value cannot be found, one
approach is to calculate the MCID within the same clin-
ical trial. In other words, the same clinical trial data
serve to calculate the MCID value, which is then applied
to each patient of the trial to determine which patient
met the MCID threshold. For instance, a clinical trial of
lumbar discectomy was used (i) to calculate the MCID
of leg and back pain (3.5 and 2.5 points for leg and back
pain, respectively, on 0–10 NRS) and (ii) to determine
the proportion of patients with improved leg and back
pain (i.e., patients with pain scores above the MCID)[21]. Using the ROC method, the authors found a MCID
of 2.5 for NRS back and 3.5 for NRS leg; when applied
to the trial data, the proportion of patients who had clin-
ically significantly improvement (met the MCID) in leg
pain and back pain was 67% and 59%, respectively.
Comparing the efficacy of two treatments in clinical trials
The MCID can be used to determine treatment efficacy
or to compare the efficacy of two active treatments in
clinical trials. To do so, first, one has to calculate the
proportion of patients in each treatment group that
meet the MCID, defined as individual patients for whom
the difference between pre- versus post-treatment pain
score is equal to or greater to the MCID threshold. Then,
the treatment groups can be compared for the proportion
of patients who meet the MCID using a standard statis-
tical method. For instance, a study evaluating transsacral
axial interbody fusion found that only 50% of patients met
the MCID of the VAS score for back pain [29]. Another
study evaluating lumbar spine surgery found that 67% of
patients met the MCID of leg pain [21].
One important error that is made when determining
treatment efficacy in clinical trials is to calculate the
mean difference (pre- versus post-treatment) pain score
for the treatment group and comparing it to the MCID
(“Pitfalls in calculation and interpretation of clinically
important differences” section). The MCID is a metric that
is based on longitudinal differences in individual patients
and should be used in the same context.
Although this seems straightforward, the clinical trial
data used to calculate the MCID have a few issues that
are inherent to all analgesic trials: (i) analgesics that are
known to be effective only result in an average decrease
in PI scores of 0.5 to 1 point on a 0–10 NRS compared
to placebo, which means that MCID values tend to be
small (10–20 mm on VAS, Table 2); (ii) the proportion
of responders (patients whose PI decreases by ≥30%) is
often 40% to 50% for effective analgesics, which means
that the % of patients who meet the MCID should be
relatively low; (iii) the placebo effect is often high, lead-
ing to a situation whereby known effective analgesics
frequently demonstrate non-significant effects compared
to placebo (failed trials); and (iv) pain is a subjective ex-
perience and pain reporting by patients may vary accord-
ing to patient characteristics and study design or conduct,
affecting the pain endpoint and therefore the % patients
who meet the MCID.
Determining treatment efficacy in individual patients
The SDD/MDC and MCID can be used by orthopedic
practitioners in the clinical setting to determine whether
an individual patient has responded to treatment based
on the patient’s change in pain score between pre- ver-
sus post-treatment. Figure 2 provides examples of three
Table 6 Level of efficacy used in OA treatment guidelines
depending on the statistical and clinical importance
(MCII) of the treatment effect
Descriptive term Condition of use
Clinically significant Statistically significant and lower
limit of CI > MCII
Possibly clinically significant Statistically significant and CI contains
the MCII
Not clinically significant Statistically significant and upper limit
of CI < MCII
True negative finding Not statistically significant and upper
limit of CI < MCII
Inconclusive finding Not statistically significant but CO
contains the MCII
From AAOS 2013 [30].
Katz et al. Journal of Orthopaedic Surgery and Research  (2015) 10:24 Page 10 of 11different cases with different response to a treatment.
Categorizing patients by level of response to treatment
should help physicians make further treatment deci-
sions for patients (continue or change treatment) and
make treatment decisions for other patients with a
similar condition.
There are important caveats to applying the MCID,
which is determined in clinical trial, to the clinical set-
ting (“Pitfalls in calculation and interpretation of clin-
ically important differences” section). First, the MCID
is derived in a homogeneous population in clinical
trial, while patients in the clinical setting are heteroge-
neous. Second, categorizing patients as responder/
non-responder can negatively affect patient manage-
ment as it does not take into account the category of
patients who are borderline responders or poor responders.
For these suboptimal responders, making an appropriate
treatment decision will require additional clinical informa-
tion regarding treatment effect.
One key problem in using the MCID in the clinical
setting is that patients may not have clinically important
changes in pain but may have substantial improvements
in function, sleep, or other clinical benefits. Thus, apply-
ing only MCID in painful orthopedic indications where
function and other outcomes are important to make
treatment decisions may not be the best approach, i.e.,
may have negative implications for patient management.
Other domains including physical functioning, emotional
functioning, and overall improvement, for which an
MCID can be calculated, should be considered. Ad-
verse effects, burden to patient, and cost should also
be taken into consideration when making treatment
choices (“Pitfalls in calculation and interpretation of
clinically important differences” section).
Using the MCID to inform guidelines
The MCID (or minimal clinically important improvement
(MCII)) derived from clinical trials is used to inform
guidelines. For example, in the OA treatment guidelines
[30], clinical significance takes into account both the stat-
istical significance of the treatment efficacy (versus pla-
cebo) and the 95% CI of the mean pain score relative to
MCII (Table 6) to flag as ineffective treatments whose
upper bound estimate of treatment efficacy remains below
the MCII threshold.
The use of the MCID or MCII as the cornerstone to
determining treatment efficacy in guidelines has many
caveats [31]. First, the MCID calculation can greatly vary
between studies, making the comparison between treat-
ments assessed in different studies very difficult. Second,
many clinical variables (disease severity, age, body weight,
activity level, comorbidities, and prior treatments) not
reflected in the MCID are important to consider when
selecting a treatment for a patient. Thus, the MCIDshould only be considered as a tool to analyze clinical trial
results that supplements, but does not replace, expert clin-
ical judgment to make decisions when treating patients
with orthopedic conditions.
Conclusions
The MCID and CID are useful tools to determine whether
a treatment produces clinically meaningful effects in a pa-
tient. However, these metrics have many pitfalls, requiring
a good understanding of the methods to calculate them
and their context of use. Orthopedic surgeons that will
use these metrics need to carefully understand them and
be aware of their pitfalls.
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